Early Superior HBV Dna Reduction with Entecavir VS. Adefovir (adv) In Chronically Infected Hbeag (+) Nucleioside Naive Adults In A 12-Week Viral Kinetics Study Trademark Details

This mark is dead with a status of Abandoned-Failure to Respond or Late Response. The last case file activity for this mark occured 12 years ago on Tuesday, November 15, 2011, according to the United State Patent & Trademark Office
Word Mark Early Superior Hbv Dna Reduction with Entecavir Vs. Adefovir (Adv) in Chronically Infected Hbeag () Nucleioside Naive Adults in a 12-Week Viral Kinetics Study
Status Dead 602 — Abandoned-Failure to Respond or Late Response

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 78844268
Status Date Tuesday, November 15, 2011
Filing Date Tuesday, November 15, 2011
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154

Case File Statements

Disclaimer with Predetermined Text "Superior Hbv Dna Reduction with Entecavir Vs. Adefovir (Adv) in Chronically Infected Hbeag () Nucleioside Naive Adults in a 12-Week Viral Kinetics Study"
Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Wednesday, March 29, 2006
First Use Anywhere Thursday, April 6, 2006
First Use In Commerce Thursday, April 6, 2006
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.